Navigation Links
Mylan Launches Generic Version of Sandostatin®
Date:4/5/2011

PITTSBURGH, April 5, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Bioniche Pharma has launched Octreotide Acetate Injection USP, pre-filled syringes (PFS), the generic version of Novartis' Sandostatin®, a treatment for a rare hormonal disorder called acromegaly. Octreotide Acetate Injection is also used to suppress or inhibit severe diarrhea associated with metastatic carcinoid tumors and vasoactive intestinal peptide tumors.

Mylan Institutional President Matt Erick said: "This approval is particularly important because it is the first and only PFS for this product – brand or generic – providing hospitals and clinics access to a preferred presentation that offers ease, accuracy and convenience of dosing. The addition of Octreotide Acetate Injection as Mylan Institutional's first PFS is a critical next step in expanding our already diverse portfolio of injectable products."

Octreotide Acetate Injection had U.S. sales of approximately $579 million for the 12 months ending Dec. 31, 2010, according to IMS Health. The product, which is available for immediate shipment, was developed by Chemi and is being manufactured by Italfarmaco; both companies are part of privately held Italian Pharmaceutical Group.

Bioniche Pharma is part of Mylan Institutional, a platform that provides differentiated pharmaceutical products to institutional customers throughout North America. Mylan Institutional's product offering includes the specialty injectables of Bioniche Pharma with the unit dose capabilities of Mylan's UDL Laboratories. Mylan Institutional's customers include group purchasing organizations, wholesalers, hospitals, surgical and radiology services, home infusion service providers, long-term care facilities, correctional facilities, specialty pharmacies, veterinary clinics and retail outlets.

Currently, Mylan has
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
2. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
3. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
4. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
5. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
6. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
7. Mylan Confirms Four First-to-File Challenges
8. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
9. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
10. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
11. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... May 16, 2013 Kitware ... solutions, today announces new Phase II SBIR funding ... continued development of an open-source, high performance computing ... integration framework enables researchers to select only the ... of simulation, computation, or analysis tasks. , ...
(Date:5/16/2013)... May 16, 2013 Scientists at the Center ... , and the California -based ... a novel therapy for reversing memory decline in mice ... find significant cognitive improvement in advanced stage AD mice. ... for reversing cognitive decline for advanced stage AD mice, ...
(Date:5/16/2013)... , May 16, 2013 /PRNewswire/ ... market research report is available in ... Competitor Analysis: Therapeutic Proteins ... http://www.reportlinker.com/p01171947/Competitor-Analysis-Therapeutic-Proteins-–-Biosimilars-Biobetters--Biosuperiors.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical   ...   The new Competitive ...
(Date:5/16/2013)... Ottawa, ON (PRWEB) May 16, 2013 DNA ... today announced ‘Spit for Africa’, a sponsorship program in conjunction ... Africa is designed to improve access and reduce the cost ... genomic projects such as the Human Heredity and Health in ... of the AfSHG. , The aim of the AfSHG ...
Breaking Biology Technology:Kitware Develops a Customizable Simulation Framework to Provide HPC for Small to Mid-Sized Manufacturers 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 5Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 6Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 7Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 8DNA Genotek Inc. Announces Spit for Africa Program 2DNA Genotek Inc. Announces Spit for Africa Program 3
... DuPont Senior,Vice President and Chief Science & Technology Officer ... in the formation of global,policy during a discussion at ... of science is to inform the policymaking process, to ... limits of what is,knowable, and what is possible," Chowdhry ...
... Massive Rebuilding Effort for Tornado-Torn ... Health Care Facility, ... struggle to rebuild following a devastating 2007 tornado,Siemens has announced that, ... Ga. facility with a new MAGNETOM ESSENZA, worth,approximately $800,000., Siemens ...
... Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced today ... trial of a second generation oral niacin receptor agonist,under ... the,treatment of atherosclerosis and other disorders. The initiation of ... are very pleased with the progress of this collaboration,investigating ...
Cached Biology Technology:DuPont Chief Science & Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum 2DuPont Chief Science & Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum 3A Magnetic Gift: Sumter Regional Hospital Receives New MRI as Charitable Donation From Siemens 2Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc. 2Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc. 3
(Date:5/17/2013)... noise of the South, but the night belongs to the ... heavy from the humidity and the sounds of wildlife. ... frogs, toads and salamanders, is the center of amphibian biodiversity ... the auditorium for their symphonic choruses, the scientists of the ... have front-row seats. , Amphibians, which rely on ...
(Date:5/17/2013)... Efficient and Sustainable Global Logistics Operations) is aiming to ... efficiency of intermodal loading systems and the boosting of ... European organisations with experience in the logistics sector and ... 17,000,000 and a duration of three and a half ... the semantic components and ontologies shared by the users, ...
(Date:5/16/2013)... (Maximizing Access to Research Careers) Program has announced ... (ENDO) 95th Annual Meeting in San Francisco, CA ... to promote the entry of students, postdoctorates and ... the basic science community and to encourage the ... Annual Meeting. , Awards are given to poster/platform ...
Breaking Biology News(10 mins):Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4New logistics services that will cut energy consumption and CO2 emissions 2
... stem cell that participates in the repair of the large ... protecting the body from infectious agents and toxins in the ... and clearing mucus from the airways. The mucus is largely ... mechanisms of normal and excessive mucus production are not well ...
... to run at much lower energy, according to researchers ... . The technology could improve efficiency for hurricane and ... (WSNs) are used to monitor ecosystems, wild and urban ... threaten species and environments, including gathering information from animal ...
... the degenerative brain disorder that disrupts memory, thought and ... According to the Alzheimer,s Association, one in eight Americans ... Now Tel Aviv University has discovered that an everyday ... to Alzheimer,s prevention. An extract found in ...
Cached Biology News:UCLA stem cell scientists discover new airway stem cell 2Greener disaster alerts 2Alzheimer's prevention in your pantry 2
... >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long been ... radiolabeled ligands selected to keep pace with ... of products and services for receptor research ... radioligands. If you do not find exactly ...
... TURBO DNase (patent pending) was developed using ... changes into the DNA binding pocket of wild-type ... of the protein for DNA. The result is ... Km for DNA, and an ability to maintain ...
Request Info...
MAb to Mouse MHC Class I H-2Kd...
Biology Products: